ライフサイエンスコーパス: obstructive pulmonary disease

1 gnosis (interstitial lung disease or chronic obstructive pulmonary disease).

2 s index, chronic kidney disease, and chronic obstructive pulmonary disease).

3 patocytes, causing liver disease and chronic obstructive pulmonary disease.

4 are widely used to treat asthma and chronic obstructive pulmonary disease.

5 outcomes of sepsis in patients with chronic obstructive pulmonary disease.

6 d during exacerbations of asthma and chronic obstructive pulmonary disease.

7 zyme inhibitors in the patients with chronic obstructive pulmonary disease.

8 nt of emphysema in participants with chronic obstructive pulmonary disease.

9 iated with early-onset emphysema and chronic obstructive pulmonary disease.

10 r cigarette smokers with and without chronic obstructive pulmonary disease.

11 moke-induced model for emphysematous chronic obstructive pulmonary disease.

12 ory cytokines involved in asthma and chronic obstructive pulmonary disease.

13 burden of the growing prevalence of chronic obstructive pulmonary disease.

14 d >=65 years, 26.8% had a history of chronic obstructive pulmonary disease.

15 cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease.

16 tory tract infections in adults with chronic obstructive pulmonary disease.

17 rbations of both cystic fibrosis and chronic obstructive pulmonary disease.

18 his might indicate an early stage of chronic obstructive pulmonary disease.

19 respiratory diseases like asthma and chronic obstructive pulmonary disease.

20 ergic receptor agonist used to treat chronic obstructive pulmonary disease.

21 yocardial infarction, and history of chronic obstructive pulmonary disease.

22 in such diseases as Alzheimer's and chronic obstructive pulmonary disease.

23 risk factors except hypertension and chronic obstructive pulmonary disease.

24 00 cells/muL, smoking, drug use, and chronic obstructive pulmonary disease.

25 f airway diseases such as asthma and chronic obstructive pulmonary disease.

26 .93) and children (1.39, 1.29-1.49), chronic obstructive pulmonary disease (1.70, 1.47-1.97), lung ca

27 ratio, 1.95; 95% CI, 1.33 to 2.86), chronic obstructive pulmonary disease (14.2%, vs. 5.6% among tho

28 (27.4%), diabetes mellitus (29.5%), chronic obstructive pulmonary disease (16.0%), and a mean logist

29 al fibrillation (6% versus 10%), and chronic obstructive pulmonary disease (4% versus 7%) in patients

30 c surgery (18% versus 12%, P<0.001), chronic obstructive pulmonary disease (5% versus 3%, P=0.004), u

31 ), respiratory cancers (111 083) and chronic obstructive pulmonary disease (83 593).

32 nclusion In women more than men with chronic obstructive pulmonary disease, a reduction in the estima

33 entilation with clinical outcomes in chronic obstructive pulmonary disease: a systematic review and m

34 Chronic obstructive pulmonary disease accounts for 3.2% of all p

35 admitted with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) often are prescri

36 onia (CAP) and acute exacerbation of chronic obstructive pulmonary disease (AECOPD) represent a major

37 thogenesis of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).

38 ycin prevents acute exacerbations of chronic obstructive pulmonary disease (AECOPDs); however, its va

39 UMEC/VI in patients with symptomatic chronic obstructive pulmonary disease and a history of exacerbat

40 Patients with chronic obstructive pulmonary disease and a short duration of sm

41 ulmonary ventilation information for chronic obstructive pulmonary disease and correlates with hyperp

42 lopment of chronic diseases, such as chronic obstructive pulmonary disease and interstitial pulmonary

43 dults is cardiovascular disease, but chronic obstructive pulmonary disease and lung cancer are import

44 the prevalence of illnesses such as chronic obstructive pulmonary disease and lung cancer, however,

45 in the FSTL1 region corresponded to chronic obstructive pulmonary disease and lung function.Conclusi

46 , drug use disorders, and history of chronic obstructive pulmonary disease and occupational lung dise

47 ericellular proteolysis occurring in chronic obstructive pulmonary disease and other diseases.

48 ad to lifelong disabilities, such as chronic obstructive pulmonary disease and vision loss.

49 eart failure, stroke, pneumonia, and chronic obstructive pulmonary disease) and a surgical diagnosis

50 respiratory disease (severe asthma, chronic obstructive pulmonary disease, and bronchiectasis) were

51 ke, cancer, heart failure, dementia, chronic obstructive pulmonary disease, and cirrhosis were statis

52 th poor clinical outcomes in asthma, chronic obstructive pulmonary disease, and cystic fibrosis; howe

53 rom cardiovascular disease, cancers, chronic obstructive pulmonary disease, and dementia in older age

54 acute respiratory distress syndrome, chronic obstructive pulmonary disease, and interstitial lung dis

55 schaemic heart disease, lung cancer, chronic obstructive pulmonary disease, and liver cancer were the

56 ad to hypoxic spells such as asthma, chronic obstructive pulmonary disease, and obstructive sleep apn

57 or stroke/transient ischemic attack, chronic obstructive pulmonary disease, and peripheral arterial d

58 tory lung diseases including asthma, chronic obstructive pulmonary disease, and pulmonary fibrosis.

59 mong patients suffering from cancer, chronic obstructive pulmonary disease, and several other chronic

60 icated conditions, including asthma, chronic obstructive pulmonary disease, and various autoimmune di

61 nce that suggests that patients with chronic obstructive pulmonary disease are more likely to have ad

62 ctional mobility, ejection fraction, chronic obstructive pulmonary disease, arrhythmia, acute kidney

63 n-CAHs for pneumonia, heart failure, chronic obstructive pulmonary disease, arrhythmia, urinary tract

64 ed risk for serious diseases such as chronic obstructive pulmonary disease as adults, no specific inv

65 ng disease (ILD) is fast approaching chronic obstructive pulmonary disease as the number one indicati

66 alysis-dependence, cancer diagnosis, chronic obstructive pulmonary disease, ascites, sepsis, smoking,

67 of diabetes and recent evidence for chronic obstructive pulmonary disease-associated kidney injury.

68 d in the lungs of humans affected by chronic obstructive pulmonary disease-associated pulmonary hyper

69 In humans with chronic obstructive pulmonary disease-associated pulmonary hyper

70 erlying diseases (diabetes mellitus, chronic obstructive pulmonary disease, asthma), shockable rhythm

71 tive respiratory diseases, including chronic obstructive pulmonary disease, asthma, and cystic fibros

72 s it pertains to the pathogenesis of chronic obstructive pulmonary disease, asthma, idiopathic pulmon

73 Pneumonia, acute chronic obstructive pulmonary disease/asthma exacerbation, septi

74 il counts, and greater prevalence of chronic obstructive pulmonary disease at recruitment.

75 ol subjects, independent of smoking, chronic obstructive pulmonary disease, BMI, renin-angiotensin-al

76 on and mortality among patients with chronic obstructive pulmonary disease but has not been well stud

77 e blood transfusion), comorbidities (chronic obstructive pulmonary disease, cancer, sepsis, ventilato

78 concentrations in a heavy smoker and chronic obstructive pulmonary disease cohort, we confirmed the e

79 he COPDGene (Genetic Epidemiology of Chronic Obstructive Pulmonary Disease) cohort.Measurements and M

80 46), were more likely to suffer from chronic obstructive pulmonary disease (COPD 30% vs 9.8%; p = 0.0

81 ilure (35.3% vs 24.5%; P < .001) and chronic obstructive pulmonary disease (COPD) (29.8% vs 24.3%; P

82 r of cases of acute exacerbations of chronic obstructive pulmonary disease (COPD) advanced by air pol

83 Chronic obstructive pulmonary disease (COPD) and asthma remain p

84 piratory diseases (CLRDs), including chronic obstructive pulmonary disease (COPD) and asthma, are the

85 Applying SmCCNet to studies on chronic obstructive pulmonary disease (COPD) and breast cancer,

86 tion (NIV) is used for patients with chronic obstructive pulmonary disease (COPD) and chronic hyperca

87 y improves survival in patients with chronic obstructive pulmonary disease (COPD) and chronic severe

88 rom patients with smoking-associated chronic obstructive pulmonary disease (COPD) and from mice chron

89 ventilation (NIPPV) with outcomes in chronic obstructive pulmonary disease (COPD) and hypercapnia is

90 Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulm

91 Chronic obstructive pulmonary disease (COPD) and idiopathic pulm

92 chronic lung diseases, particularly chronic obstructive pulmonary disease (COPD) and idiopathic pulm

93 therapy to appropriate patients with chronic obstructive pulmonary disease (COPD) and interstitial lu

94 s prevalent in chronic diseases such Chronic Obstructive Pulmonary Disease (COPD) and is associated w

95 nist (LABA) therapy in patients with chronic obstructive pulmonary disease (COPD) are limited.

96 at-risk groups such as patients with chronic obstructive pulmonary disease (COPD) are poorly understo

97 Patients with chronic obstructive pulmonary disease (COPD) are susceptible to

98 y, and changes in symptoms using the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test and

99 ssment of emphysema in patients with chronic obstructive pulmonary disease (COPD) at high spatial res

100 /VI) versus UMEC/VI in patients with chronic obstructive pulmonary disease (COPD) at risk of future e

101 ation is recommended for people with chronic obstructive pulmonary disease (COPD) by all major COPD c

102 uals without spirometric evidence of chronic obstructive pulmonary disease (COPD) by current diagnost

103 Rationale: Chronic obstructive pulmonary disease (COPD) can develop not onl

104 A relative drop in FEV(1) >=10% in chronic obstructive pulmonary disease (COPD) candidates was asso

105 Chronic obstructive pulmonary disease (COPD) comprises chronic b

106 Chronic obstructive pulmonary disease (COPD) constitutes a major

107 er adults at high risk of developing chronic obstructive pulmonary disease (COPD) could lead to imple

108 United States receive a diagnosis of chronic obstructive pulmonary disease (COPD) each year, and it i

109 and former smokers with and without chronic obstructive pulmonary disease (COPD) enrolled in the pro

110 Rationale: Chronic obstructive pulmonary disease (COPD) exacerbations are p

111 Patients hospitalized for chronic obstructive pulmonary disease (COPD) exacerbations have

112 hinovirus (HRV) is a common cause of chronic obstructive pulmonary disease (COPD) exacerbations.

113 Respiratory viral infection causes chronic obstructive pulmonary disease (COPD) exacerbations.

114 RATIONALE: Patients with chronic obstructive pulmonary disease (COPD) frequently have alb

115 Rationale: Chronic obstructive pulmonary disease (COPD) has been associated

116 re use and death among patients with chronic obstructive pulmonary disease (COPD) has been tested.

117 Background Pulmonary imaging of chronic obstructive pulmonary disease (COPD) has focused on CT o

118 f eosinophils in blood and sputum in chronic obstructive pulmonary disease (COPD) have been associate

119 Background Smokers with chronic obstructive pulmonary disease (COPD) have smaller left v

120 ospitalizations for exacerbations of chronic obstructive pulmonary disease (COPD) improves exercise c

121 tion between alcohol consumption and chronic obstructive pulmonary disease (COPD) incidence has not b

122 Comorbidities such as diabetes and chronic obstructive pulmonary disease (COPD) increase patients'

123 udy was to diagnose and characterise chronic obstructive pulmonary disease (COPD) into its forms, pat

124 Chronic obstructive pulmonary disease (COPD) is a common and pro

125 Chronic obstructive pulmonary disease (COPD) is a complex and he

126 Chronic obstructive pulmonary disease (COPD) is a debilitating l

127 Chronic obstructive pulmonary disease (COPD) is a debilitating l

128 Chronic obstructive pulmonary disease (COPD) is a heterogeneous

129 Chronic obstructive pulmonary disease (COPD) is a lung disorder

130 Chronic obstructive pulmonary disease (COPD) is a major global h

131 Chronic Obstructive Pulmonary Disease (COPD) is a prevalent chro

132 Chronic obstructive pulmonary disease (COPD) is a progressive co

133 Chronic obstructive pulmonary disease (COPD) is an inflammatory

134 patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) is associated with

135 BackgroundChronic obstructive pulmonary disease (COPD) is associated with

136 Chronic obstructive pulmonary disease (COPD) is characterized by

137 Chronic obstructive pulmonary disease (COPD) is characterized by

138 Chronic obstructive pulmonary disease (COPD) is characterized by

139 Chronic obstructive pulmonary disease (COPD) is characterized by

140 Chronic obstructive pulmonary disease (COPD) is induced by cigar

141 lerance to exercise in patients with chronic obstructive pulmonary disease (COPD) is not known.

142 Chronic obstructive pulmonary disease (COPD) is one such conditi

143 Chronic obstructive pulmonary disease (COPD) is regarded as a di

144 Chronic obstructive pulmonary disease (COPD) is the leading caus

145 Chronic obstructive pulmonary disease (COPD) is the most common

146 Chronic Obstructive Pulmonary Disease (COPD) is the third leadin

147 lung function assessment, asthma and chronic obstructive pulmonary disease (COPD) management, metabol

148 Chronic obstructive pulmonary disease (COPD) may originate in ea

149 Asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) repre

150 s (0.8%; 0%-3.5%; n = 15), or stable chronic obstructive pulmonary disease (COPD) patients (1.2%; 0.3

151 Some of the Chronic Obstructive Pulmonary Disease (COPD) patients engaged in

152 Exercise intolerance is common in chronic obstructive pulmonary disease (COPD) patients.

153 r tertiary lymphoid organs (TLOs) in chronic obstructive pulmonary disease (COPD) progression.

154 y exacerbation risk in patients with chronic obstructive pulmonary disease (COPD) rely on a history o

155 e role of environmental exposures in chronic obstructive pulmonary disease (COPD) remains inconclusiv

156 ale: The decades-long progression of chronic obstructive pulmonary disease (COPD) renders identifying

157 erging models for predicting risk of chronic obstructive pulmonary disease (COPD) require external va

158 current guidelines, the diagnosis of chronic obstructive pulmonary disease (COPD) requires a ratio of

159 The pathology and impact of chronic obstructive pulmonary disease (COPD) results from an abn

160 Although chronic obstructive pulmonary disease (COPD) risk is strongly in

161 lial cells, those from patients with chronic obstructive pulmonary disease (COPD) show higher IFN res

162 panic white smokers with and without chronic obstructive pulmonary disease (COPD) using blood samples

163 abilitation after an exacerbation of chronic obstructive pulmonary disease (COPD) was associated with

164 Rationale: Treatment of chronic obstructive pulmonary disease (COPD) with inhaled cortic

165 ronchopulmonary dysplasia (BPD); and chronic obstructive pulmonary disease (COPD)).

166 ions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and asthma.

167 erous clinical conditions, including chronic obstructive pulmonary disease (COPD), and is associated

168 nditions (such as cancer, arthritis, chronic obstructive pulmonary disease (COPD), and others) are as

169 espiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), and pulmonary fibr

170 o determine the relationship between chronic obstructive pulmonary disease (COPD), asthma and interst

171 D), cerebrovascular accidents (CVA), chronic obstructive pulmonary disease (COPD), asthma, diabetes m

172 and may enable improved treatment of chronic obstructive pulmonary disease (COPD), asthma, or urinary

173 ediction of presence and severity of chronic obstructive pulmonary disease (COPD), based on the pulmo

174 enotyping and risk stratification in chronic obstructive pulmonary disease (COPD), but few large long

175 nchyma of smokers that might overlap chronic obstructive pulmonary disease (COPD), but studies on the

176 erved in the airway in patients with chronic obstructive pulmonary disease (COPD), but their clinical

177 in patients with moderate or severe chronic obstructive pulmonary disease (COPD), but these findings

178 Chronic obstructive pulmonary disease (COPD), diagnosed by reduc

179 deficiency (AATD) is associated with chronic obstructive pulmonary disease (COPD), even among never-s

180 Rationale: In patients with chronic obstructive pulmonary disease (COPD), increased activity

181 oups including cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), interstitial lung

182 c airway diseases such as asthma and chronic obstructive pulmonary disease (COPD), together with thei

183 and lavage fluid of individuals with chronic obstructive pulmonary disease (COPD), when compared to h

184 older individuals and in those with chronic obstructive pulmonary disease (COPD), whereas shorter-te

185 An obesity paradox in chronic obstructive pulmonary disease (COPD), whereby overweight

186 radiofrequency ablation therapy for chronic obstructive pulmonary disease (COPD), which durably disr

187 Chronic obstructive pulmonary disease (COPD), which is most comm

188 life, is diminished in patients with chronic obstructive pulmonary disease (COPD), with mounting evid

189 Smoking is a major risk factor for chronic obstructive pulmonary disease (COPD), yet much of COPD r

190 s for the pharmacologic treatment of chronic obstructive pulmonary disease (COPD).

191 s common in patients with asthma and chronic obstructive pulmonary disease (COPD).

192 way ecology is altered in asthma and chronic obstructive pulmonary disease (COPD).

193 l burden in patients with asthma and chronic obstructive pulmonary disease (COPD).

194 anism(s) of action of roflumilast in chronic obstructive pulmonary disease (COPD).

195 (RV shrinkage) are both described in chronic obstructive pulmonary disease (COPD).

196 AL fluid and plasma of subjects with chronic obstructive pulmonary disease (COPD).

197 such as silicosis, lung cancer, and chronic obstructive pulmonary disease (COPD).

198 such as asthma, cystic fibrosis, and chronic obstructive pulmonary disease (COPD).

199 g tissue and that from patients with chronic obstructive pulmonary disease (COPD).

200 mber 13A) GWAS locus associated with chronic obstructive pulmonary disease (COPD).

201 ts use in the clinical management of chronic obstructive pulmonary disease (COPD).

202 od eosinophil count in patients with chronic obstructive pulmonary disease (COPD).

203 ents who have acute exacerbations of chronic obstructive pulmonary disease (COPD).

204 y, progression, and heterogeneity of chronic obstructive pulmonary disease (COPD).

205 t risk factor for the development of chronic obstructive pulmonary disease (COPD).

206 spectively, causing the hallmarks of chronic obstructive pulmonary disease (COPD).

207 y inflammatory conditions, including chronic obstructive pulmonary disease (COPD).

208 ially induced acute exacerbations of chronic obstructive pulmonary disease (COPD).

209 bidity or mortality in patients with chronic obstructive pulmonary disease (COPD).

210 ts, including clinical datasets from chronic obstructive pulmonary disease (COPD).

211 entially toxic substances and causes chronic obstructive pulmonary disease (COPD).

212 (12%) in the United States who have chronic obstructive pulmonary disease (COPD).

213 ssues, including cystic fibrosis and chronic obstructive pulmonary disease (COPD).

214 ality and is key to the diagnosis of chronic obstructive pulmonary disease (COPD).

215 ls of benralizumab for patients with chronic obstructive pulmonary disease (COPD).

216 tilation heterogeneity are common in chronic obstructive pulmonary disease (COPD).

217 (HTN), atrial fibrillation (AF), and chronic obstructive pulmonary disease (COPD).

218 es on the course and pathogenesis of chronic obstructive pulmonary disease (COPD).

219 eptor patched homolog 1 (PTCH1) with chronic obstructive pulmonary disease (COPD).

220 ospital readmission in patients with chronic obstructive pulmonary disease (COPD).

221 (HHIP) are robustly associated with chronic obstructive pulmonary disease (COPD).

222 ons for select conditions, including chronic obstructive pulmonary disease (COPD).

223 ors and an inhaled corticosteroid in chronic obstructive pulmonary disease (COPD).

224 own to exert therapeutic efficacy in chronic obstructive pulmonary disease (COPD).

225 cation of gene expression studies in chronic obstructive pulmonary disease (COPD).

226 associated with worse outcomes than chronic obstructive pulmonary disease (COPD).

227 lung structure in conditions such as chronic obstructive pulmonary disease (COPD).

228 RNAs in lung tissue of patients with chronic obstructive pulmonary disease (COPD).

229 mation and airway wall remodeling in chronic obstructive pulmonary disease (COPD).

230 CF), non-CF bronchiectasis (BE), and chronic obstructive pulmonary disease (COPD).

231 have been associated with asthma and chronic obstructive pulmonary disease (COPD).

232 life, is diminished in patients with chronic obstructive pulmonary disease (COPD).

233 cytokine found to be associated with chronic obstructive pulmonary disease (COPD).

234 ia, and 1830 (1.1%) participants had chronic obstructive pulmonary disease (COPD).

235 Smoking is a major risk factor for chronic obstructive pulmonary disease (COPD); however, more than

236 ular blood flow (PMBF) is reduced in chronic obstructive pulmonary disease (COPD); however, the effec

237 ses (0.26%; 95% PI: 0.07, 0.46), and chronic obstructive pulmonary disease (COPD; 0.34%; 95% PI: 0.12

238 ith comorbid allergy (P = 0.045) and chronic obstructive pulmonary disease (COPD; P = 0.015).

239 f presence of breathlessness, higher chronic obstructive pulmonary disease [COPD] prevalence, materna

240 ), COPDGene (Genetic Epidemiology of Chronic Obstructive Pulmonary Disease [COPD]), Framingham Heart,

241 strains isolated from patients with chronic obstructive pulmonary disease, COPD.

242 The Genetic Epidemiology of Chronic Obstructive Pulmonary Disease (COPDGene) study, which be

243 e investigated whether patients with chronic obstructive pulmonary disease could safely receive nonin

244 tes, coronary heart disease, stroke, chronic obstructive pulmonary disease, depression, arthritis, ca

245 en (NOx), and ozone on characterized chronic obstructive pulmonary disease exacerbations in a regress

246 CS or to elastase, and patients with chronic obstructive pulmonary disease, exhibited significantly d

247 Increased risk of asthma and chronic obstructive pulmonary disease has been reported in peopl

248 eases, obesity, diabetes, asthma and chronic obstructive pulmonary disease have become major healthca

249 prevalent cases of diabetes, cancer, chronic obstructive pulmonary disease, heart disease, and death.

250 e (HR, 1.04; 95% CI, 1.00-1.09), and chronic obstructive pulmonary disease (HR, 1.09; 95% CI, 1.03-1.

251 s for asthma in children and adults, chronic obstructive pulmonary disease, hypertension, diabetes, o

252 C(2)HEST (coronary artery disease or chronic obstructive pulmonary disease, hypertension, elderly, sy

253 ry co-morbidities like pneumonia and chronic obstructive pulmonary disease) improved all-case agreeme

254 6 million to 6.8 million) DALYs from chronic obstructive pulmonary disease in 2015.

255 ood, suggesting an increased risk of chronic obstructive pulmonary disease in later adulthood.

256 lt in ~300 000 premature deaths from chronic obstructive pulmonary disease in the two countries.

257 e, smoking status, hypertension, and chronic obstructive pulmonary disease included in multivariable

258 chest CT, such as for osteoporosis, chronic obstructive pulmonary disease, interstitial lung disease

259 Chronic obstructive pulmonary disease is a complicated disease r

260 Rationale: Chronic obstructive pulmonary disease is an independent risk fac

261 Chronic obstructive pulmonary disease is characterized by incomp

262 was detected by Western blotting in chronic obstructive pulmonary disease lungs and CS extract-expos

263 hic pulmonary fibrosis (n = 13), and chronic obstructive pulmonary disease (n = 15), were analyzed fo

264 , 4 of dementia (n = 1036), and 3 of chronic obstructive pulmonary disease (n = 441).

265 y symptoms compatible with asthma or chronic obstructive pulmonary disease, normal spirometry, and no

266 of workplace exposures to asthma and chronic obstructive pulmonary disease on a population level, but

267 ightly older and more likely to have chronic obstructive pulmonary disease or heart failure.

268 ectives: To determine whether PGD in chronic obstructive pulmonary disease or interstitial lung disea

269 ed with control subjects, but not in chronic obstructive pulmonary disease or sarcoidosis.

270 arthritis; OR 1.71; asthma: OR 1.56; chronic obstructive pulmonary disease: OR 1.65; cancer: OR 1.23;

271 Chronic obstructive pulmonary disease (P = 0.043), the cessation

272 ), arterial hypertension (P = 0.45), chronic obstructive pulmonary disease (P = 0.73), chronic kidney

273 On multivariable analysis, chronic obstructive pulmonary disease (P=0.024), prior use of co

274 seases, including asthma (PAF, 16%); chronic obstructive pulmonary disease (PAF, 14%); chronic bronch

275 Chronic obstructive pulmonary disease patients receiving noninva

276 an accepted supportive treatment in chronic obstructive pulmonary disease patients.

277 derately impaired ejection fraction, chronic obstructive pulmonary disease, peripheral vascular disea

278 acute respiratory infection, asthma, chronic obstructive pulmonary disease, pneumonia, and all respir

279 ity, alcohol, sleep apnea, diabetes, chronic obstructive pulmonary disease, previous myocardial infar

280 sease (respiratory death or nonfatal chronic obstructive pulmonary disease, pulmonary tuberculosis, p

281 th patients without injury (Clinical Chronic Obstructive Pulmonary Disease Questionnaire: median, 0.2

282 patient-reported breathing (Clinical Chronic Obstructive Pulmonary Disease Questionnaire: median, 1.0

283 Chronic obstructive pulmonary disease refers to a group of disea

284 , clade A, member 1), in determining chronic obstructive pulmonary disease risk and severity is contr

285 ed for those with moderate or severe chronic obstructive pulmonary disease (risk ratio, 2.89; 95% con

286 sively increased from mild to severe chronic obstructive pulmonary disease severity.

287 ily mortality due to respiratory and chronic obstructive pulmonary disease specifically were positive

288 the progression of such disorders as chronic obstructive pulmonary disease, systemic sclerosis, and k

289 The IMPACT (Informing the Pathway of Chronic Obstructive Pulmonary Disease Treatment) trial demonstra

290 the IMPACT (Informing the Pathway of Chronic Obstructive Pulmonary Disease Treatment) trial, fluticas

291 lar disease, chronic kidney disease, chronic obstructive pulmonary disease, valvular heart disease, t

292 In patients with asthma or chronic obstructive pulmonary disease, viral infections, includi

293 Coronary heart disease and asthma or chronic obstructive pulmonary disease were the most common comor

294 age III and IV, and 29 patients with chronic obstructive pulmonary disease were used as control subje

295 Smoking also causes chronic obstructive pulmonary disease, which is treated with bet

296 All patients with chronic obstructive pulmonary disease who received angiotensin-c

297 patients 65 years or younger without chronic obstructive pulmonary disease who were admitted to our h

298 hat interventions to help those with chronic obstructive pulmonary disease who wish to remain in work

299 on and Quality of Life Assessment in Chronic Obstructive Pulmonary Disease with Closed Triple Therapy

300 isease pathogenesis, for example, in chronic obstructive pulmonary disease, yet the mechanisms that r